---
title: "Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286968711.md"
description: "Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 8.04% to $9.15 on Tuesday, marking the fourth consecutive day of losses. The stock is now 55.50% below its 52-week high of $20.56. In comparison, competitors Vanda Pharmaceuticals Inc. and Fortress Biotech Inc. had mixed performances, with Vanda down 1.48% and Fortress up 2.02%. Overall, the NASDAQ Composite Index dropped 0.84%."
datetime: "2026-05-19T21:19:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286968711.md)
  - [en](https://longbridge.com/en/news/286968711.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286968711.md)
---

# Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) shed 8.04% to $9.15 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index falling 0.84% to 25,870.71 and Dow Jones Industrial Average falling 0.65% to 49,363.88.

This was the stock's fourth consecutive day of losses.

Corbus Pharmaceuticals Holdings Inc. closed 55.50% below its 52-week high of $20.56, which the company achieved on October 20th.

The stock underperformed when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc. (VNDA) fell 1.48% to $5.99, Fortress Biotech Inc. (FBIO) rose 2.02% to $2.53, and Viking Therapeutics Inc. (VKTX) fell 1.01% to $28.40.

Trading volume (324,136) eclipsed its 50-day average volume of 264,933.

Data source: Dow Jones Market Data, FactSet. Data compiled May 19, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-19-26 1719ET

### Related Stocks

- [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [VNDA.US](https://longbridge.com/en/quote/VNDA.US.md)
- [FBIO.US](https://longbridge.com/en/quote/FBIO.US.md)
- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)
- [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md)

## Related News & Research

- [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)
- [RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)](https://longbridge.com/en/news/286342985.md)
- [Brokers Offer Predictions for CRBP Q2 Earnings](https://longbridge.com/en/news/286408539.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)